Product Description
For Periodontal Diseases (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT05188924)
Mechanisms of Action: TGFb Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dongkook
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Periodontal Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05188924 |
DKF-306-P4 | P4 |
Unknown status |
Periodontal Diseases |
2022-06-01 |
2023-12-05 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|